Pfizer Receives European Commission Approval for Vyndaqel in ATTR Cardiomyopathy

Pfizer today announced that the European Commission has approved Vyndaqel (tafamidis meglumine) for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults in the European Union. The approval was based on the same pivotal ATTR-ACT trial data that supported the FDA approval, demonstrating significant reductions in cardiovascular mortality and hospitalizations. This approval makes Vyndaqel available to ATTR-CM patients across all EU member states. Pfizer is committed to ensuring broad patient access to Vyndaqel in Europe and continues to study tafamidis in other ATTR-related conditions.